Loading stock data…
$10.31+0.13 (+1.28%)
ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally.
ADMA Biologics, Inc. in the Healthcare sector is trading at $10.31 with a market capitalization of $2.2B. Wall Street consensus targets $17.00 (4 analysts), implying a +64.9% move over the next 12 months. The stock is currently 50% below its 52-week high of $20.46, remaining 9.8% below its 200-day moving average. On fundamentals, Piotroski 6/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 80/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $124.39M↑ | $114.49M↓ | $139.16M↑ | $134.22M↑ | $121.98M |
| Gross Profit | $86.28M↑ | $80.75M↓ | $88.82M↑ | $75.63M↑ | $67.23M |
| Operating Income | $52.45M↑ | $50.29M↓ | $62.75M↑ | $51.01M↑ | $42.80M |
| Net Income | $37.82M↓ | $45.33M↓ | $49.38M↑ | $36.43M↑ | $34.22M |
ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company operates ...